Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Cislini Jeff

Anders Jack

Mancini Anthony

GOLDSMITH MARK A

Kelsey Stephen Michael

Horn Margaret A

Erasca, Inc. faces a securities fraud class action lawsuit after disclosing a patent infringement allegation from Revolution Medicines on April 27, 2026, followed by a patient death in its ERAS-0015 Phase 1 trial on April 28, 2026. The stock plummeted 48.3% on April 28 after the death disclosure. The lawsuit alleges the company made materially false statements about ERAS-0015's preclinical data and failed to disclose material risks. The deadline to file a lead plaintiff motion is August 10, 2026.

Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims preclinical data was based on improper comparisons and lacked reasonable basis. On April 27, 2026, Erasca disclosed a patent infringement assertion from Revolution Medicines and reported a patient death in Phase I trials, causing the stock to plummet nearly 59% over two trading days. Investors with substantial losses can seek appointment as lead plaintiff by August 10, 2026.

ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. The deadline to seek lead plaintiff status is August 10, 2026.

ERAS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons to Revolution Medicines and placed the company at risk of patent and trade secret violations. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.

Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Erasca, Inc. (NASDAQ: ERAS) stock plummeted 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy and intellectual property protection. The disclosures wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. On April 28, 2026, Erasca disclosed a patent infringement letter from Revolution Medicines, causing the stock to plummet 48% from $19.15 to $9.90 per share.

(NASDAQ:ERAS) ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm

Research-driven thematic investor & swing trader. Not financial advice

Subscribe: https://t.co/tRfuPuBAXn

Venu

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Pharmdca

Finding hidden value in under-followed companies. Posts are not advice. Do your own due diligence.

Jordan Alexander

Trading & Investing Education 
Inventor : Ripster Cloud System  
Founder: Tenet Trade Group
https://t.co/0qpaN2fM0W
 https://t.co/GP2vE0fon3

Revolution Medicines Inc (RVMD) Stock Price, Analysis & Trade Signals